Pharmafile Logo

Archetypes: Rethinking go-to-market expectations to drive commercial success

In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the implications for products and portfolios across the development life cycle.

It is no secret that drug development and commercialization is a lengthy, complex, and costly process entrenched with a high degree of uncertainty.

Today, the industry is navigating one of the most complex environments yet as it tackles a number of challenges and risks, including more limited access to and the increasing cost of capital; regulatory and policy changes that are leading to declining reimbursement, more complex access pathways and shorter exclusivity time in market; and slower sales growth leading to declining profitability. These trends are compounding an already challenging landscape to develop and market products successfully.

The market is evolving in ways that are rendering traditional approaches to launch and commercialization no longer tenable or fit for purpose. In this white paper, our consultants explain how biopharmaceutical leaders can navigate the current macroeconomic trends through a bespoke approach to archetyping. The frameworks provided will drive an understanding of which tailored launch and commercialization approach is right for the business and product, uncovering clarity and efficiencies across teams, and helping you to realize the product’s full potential. This more tailored approach to launch and commercialization comprises a fundamental rethink of go-to-market expectations and the optimal delivery models to maximize commercial success.

Read on to learn about:

  • The macroeconomic and macrostrategic trends impacting commercialization today, including global policy developments, rising inflation, and increasingly complex customer journeys
  • How the biopharmaceutical industry is refocusing and restructuring in response to these trends
  • An in-depth introduction to archetypes: The foundation of a tailored commercial strategy for the modern market
  • Our two-step archetyping assessment framework to help you robustly define and deliver commercial success for your product

DOWNLOAD THE WHITEPAPER HERE

This content was provided by Avalere Health

Company Details

 Latest Content from  Avalere Health 

Avalere Health appoints new President of Medical to lead a tech-enabled future of medical affairs

Avalere Health appoints seasoned industry executive Effie Baoutis as President of Medical.

Fishawack Health becomes Avalere Health, uncovering the potential in every product and the possibilities for every patient

As a single united organization, the company seamlessly connects science and creativity, technology and data, and ability and agility to ensure patients receive life-changing innovations faster.

Industry leader Amar Urhekar joins Fishawack Health as Chief Operating Officer to integrate interdisciplinary teams across capabilities

As Chief Operating Officer, Amar will unite global teams to drive innovation, enhance client solutions, and accelerate growth.

Fishawack Health appoints Chief People Officer to spearhead integration of talent and culture across geographies

Fishawack Health welcomes Harriet Shurville to the team as Chief People Officer to spearhead integration efforts, champion diversity and inclusion, and cultivate an environment where interdisciplinary teams thrive.

Archetypes: Rethinking go-to-market expectations to drive commercial success

In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...

Fishawack Health deepens key capabilities and builds an integrated delivery model under new Chief Marketing and Creative Officer

Polymath marketer Ryan Mason leads the newly expanded group, and Jeffrey D. Erb has been tapped to grow the media and analytics team as Chief Media Officer.

Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment

Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...

The challenges of reimbursement and innovative pricing for cell and gene therapies

Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of...

Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes

Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech...

Fishawack Health welcomes Mario Muredda as its new President of Marketing

Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.